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Room locations and notes 
 
 
• General Sessions and Workshops will be held in Mali III-IV. 
• Poster Sessions will be in Mali I-II.  
• Meals will be in Soutana 1-2. The conference banquet location will be announced on 
site. 
• The ECI office is the Meeting Planner Office. 
• Audio, still photo and video recording by any device (e.g., cameras, cell phones, laptops, 
PDAs, watches) is strictly prohibited during the technical sessions, unless the author and 
ECI have granted prior permission. 
• Speakers – Please have your presentation loaded onto the conference computer prior to 
the session start (preferably the day before). 
• Speakers – Please leave discussion time as previously directed by your session chair. 
• Please do not smoke at any conference functions. 
• Turn your mobile telephones to vibrate or off during technical sessions. 
• Please write your name on your program so that it can be returned to you if lost or 
misplaced. 
• After the conference, ECI will send an updated participant list to all participants. Please 
check your listing now and if it needs updating, you may correct it at any time by logging 
into your ECI account. 
• Emergency Contact Information: Because of privacy concerns, ECI does not collect or 
maintain emergency contact information for conference participants.  If you would like to 
have this information available in case of emergency, please use the reverse side of 
your name badge. 
  
Sunday, June 17, 2018 
 
14:00 – 16:00 Conference check-in 
 
16:30 – 18:30 Workshop 1: Meet the Funders in Global Health 
Moderators: Vivian Hsu, Bill & Melinda Gates Foundation; 
Torey de Rozario, Bill & Melinda Gates Foundation; 
Tarit Mukhopadhyay, University College London 
 
Objectives: 
● To connect scientists from academia and industry to organizations who fund innovations 
in Global Health, and to provide greater insight on how to gain access to those funding 
streams 
 
● To hear from Bill & Melinda Gates Foundation grantees on their experience in working 
with a funding organization and to hear an overview of their funded technology 
 
● Ultimately, we aim to support continued funding of innovative technology to further 
vaccine development and manufacturing for global needs 
 
Opening 
Vivian Hsu, Bill & Melinda Gates Foundation 
 
Meet the funders 
1. Bill & Melinda Gates Foundation (BMGF), Torey de Rozario 
2. Global Health Investment Fund (GHIF), Glenn Rockman 
3. The National Institute for Innovations in Manufacturing (NIIMBL), Chris Roberts 
4. Coalition for Epidemic Preparedness Innovations (CEPI), Simone Blayer 
 
BMGF Grantees 
1. UCL- ULTRA Platform Grant, Tarit Mukhopadhyay & Lourdes Velez Suberbie 
2. University of Kansas Center for Research- MSA, David Volkin 
3. Vaxess- Microneedles Platform Technology Grant, Michael Schrader 
 
Open discussion 




19:00 – 20:00 Opening Keynote 
The impact of vaccines worldwide and the challenges to achieve universal immunization 
Dr. Alejandro Cravioto, Chair of WHO Strategic Advisory Group of Experts (SAGE) and Faculty 
 Medicine of the Universidad National Autonoma de Mexico 
 
  20:00 – 22:00    Opening Reception Dinner
Monday, June 18, 2018 
 
07:00 – 08:30 Breakfast 
 
08:30 – 10:30 Session 1: Technological and Clinical Avances in Vaccinology (I) 
Session Chairs: David Weiner, The Wistar Institute, USA; 
Frank Bähner, CureVac AG, Germany 
 
08:30 – 09:10 Lead talk: 
Structure-based vaccines for respiratory viruses 
Dr. Barney Graham, Deputy Director of the Vaccine Research Center of the NIH, USA 
 
09:10 – 09:35 mRNA Vaccines: On the progress from promise to reality 
Hari Pujar, Moderna, USA 
 
09:35 – 10:00 RNActive®-An mRNA-based vaccine technology for next generation prophylactic vaccines 
Edith Jasny, Senior Scientist CureVac AG, Tübingen, Germany 
 
10:00 – 10:25 Virus-like particle vaccines against BK and JC polyomaviruses 
Diana V. Pastrana, NCI/NIH, USA 
 
10:25 – 10:55 Coffee break (Sponsored by GE Healthcare and GSK) 
 
10:55 – 12:35 Session 2: Technological and Clinical Advances in Vaccinology (II) 
Session Chairs: Udo Reichl, Max Planck Institute, Germany; 
Hari Pujar, Moderna Therapeutics, USA 
 
10:55 – 11:20 Molecular quality engineering for low cost vaccine production 
Kerry Routenberg Love, Koch Cancer Institute at MIT, USA 
 
11:20 – 11:45 Single-cell analysis uncovers a novel influenza A virus-derived defective 
interfering particle for antiviral therapy 
Sascha Young Kupke, Max Planck Institute for Dynamics of Complex Technical Systems 
Magdeburg, Germany 
 
11:45 – 12:10 Persistent antibody clonotypes dominate the serum response to influenza 
following repeated vaccination over multiple years 
Jiwon Lee, University of Texas at Austin, USA 
 
12:10 – 12:35 Pan-HA antibodies confer protection in mice against influenza 
Aziza Manceur, National Research Council, Canada 
 
12:35 – 14:00 Lunch  
 
14:00 – 15:30 Workshop 2: Advanced Technologies, Equipment and Instrumentation for Vaccine    
Manufacturing 
Moderators: Charles Lutsch, Sanofi-Pasteur, France; 




Optimisation of a flocculation step using a scale-down model with 3D-printed impellers 
and focused beam reflectance measurement (FBRM) particle-size monitoring. 
Francis DiGennaro, Merck & Co., Inc., USA 
 
CRISPR-dCAS9 for controlling Baculovirus replication and increasing production of 
Virus-Like particles 







Monday, June 18, 2018 (continued) 
 
EXPISF - A chemically-defined Baculovirus-based expression system for enhanced 
protein production in SP9 Cells. 
Maya Yovcheva, Thermo Fischer Scientific Inc., USA 
 
Fully automated high-throughput process development for the novel purification of 
Rotavirus Vaccines. 
Shaleem I. Jacob, University College London, UK 
 
Influenza virus capture using membrane chromatography: Improving selectivity by matrix 
design and pseudo-affinity ligand interactions 
Stefan Fischer-Frühholtz, Sartorius Stedim Biotech, Germany 
 
A scalable adenovirus production process, from cell culture to purified bulk 
Åsa Hagner-McWhirter, GE Healthcare, Sweden 
 
     Panel Discussion (all speakers) 
 
15:30 – 16:00 Coffee break (Sponsored by McGill University - Faculty of Engineering) 
 
16:00 – 18:20 Session 3: Bioprocessing Advances in Vaccine Manufacturing (I)  
 ( Sponsored by Sartorius Stedim Biotech GmbH) 
 Session Chairs: Linda Lua, Queensland University, Australia; Richard 
Peluso, Merck and Co., USA 
 
16:00 – 16:40 Lead talk: 
The story of a successful biotech (ad)venture: The development of Flublok 
Manon Cox, NextWaveBio, USA 
 
16:40 – 17:05 Accelerating bioprocess development by analysis of all available data: A USP case study 
Diego Suarez-Zuluaga, Intravacc, Netherlands 
 
17:05 – 17:30 Purifying viruses with a sheet of paper: Single-use steric exclusion chromatography as a 
capture platform for vaccine candidates 
Pavel Marichal-Gallardo, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
17:30 – 17:55 Vero SF technology platform: Strategy for rapid and effective vaccine development; 
flavivirus vaccines case study 
Nicolas Sève, Sanofi Pasteur, France 
 
17:55 – 18:20 Bioprocess intensification for production of a Peste des petits ruminants virus (PPRV) 
vaccine 
Manuel J.T. Carrondo, iBET, Portugal 
 
18:30 – 20:00 Dinner 
 
20:00 – 22:00 Poster session 1 and Social Hour
Tuesday, June 19, 2018 
 
07:00 – 08:30 Breakfast 
 
08:30 – 10:30 Session 4: Bioprocessing Advances in Vaccine Manufacturing (II) 
(Sponsored by Takeda Vaccines, Inc.) 
Session Chairs: Francesc Godia, UAB, Spain; 
Manon Cox, NextWaveBio, USA 
 
08:30 – 09:10 Lead talk: 
Developing vaccines for low resource settings through product development partnerships 
(PDPs) 
Dr. David Kaslow, Vice President, Essential Medicines, and Director, the PATH Center for 
Vaccine Innovation and Access, USA 
 
09:10 – 09:30 Continuous purification of cell culture-derived influenza A virus particles through pseudo- 
affinity membrane chromatography 
A. Raquel Fortuna, Max Planck Institute for Dynamics of Complex Technical Systems, Germany 
 
09:30 – 09:50 Integrated scalable cyto-technology for recombinant protein bioprocessing 
J. Christopher Love, Koch Institute at MIT, USA 
 
09:50 – 10:10 Low-cost cell-based production platform for seasonal and pandemic influenza vaccines 
Alan Yung-Chih Hu, NIIDV/NHRI, Taiwan 
 
10:10 – 10:30 Polymer grafted chromatography media for direct capture and high-resolution purification 
of enveloped virus-like particles 
Patricia Pereira Aguilar, University of Natural Resources and Life Sciences Vienna, Austria 
10:30 – 11:00 Coffee break (Sponsored by Medicago and Sanofi Pasteur) 
11:00 – 11:20 Virus-like particles (VLPs) as a platform for the development of yellow fever and Zika virus 
vaccine candidate 
Renata Alvim, Federal University of Rio de Janeiro (UFRJ), Brazil 
 
11:20 – 11:40 Manufacturing strategies for sustainable supply of ultra-low cost vaccines for global 
health 
Tania Pereira Chilima, University College London, United Kingdom 
 
11:40 – 12:00 A tailor-made purification strategy for oncolytic measles viruses using membrane-based 
processes 
Daniel Loewe, University of Applied Sciences Mittelhessen, Germany 
 
12:00  Boxed lunches available for pick up 
12:20 – 13:40 Workshop 3: Genomics and Systems Biotechnology in Vaccine Development 
Moderators: Wei-Shou Hu, University of Minnesota, USA; 




Options and challenges for systems biology driven cell line development in virus 
production 
Udo Reichl, Max-Planck Institute for Dynamics of Complex Technical Systems, Germany 
 
Acceleration and intensification of influenza pandemic seed stock candidate vaccine 
production from HA and NA sequence identification 







Tuesday, June 19, 2018 (continued) 
 
FluChip-8G:  Influenza Genotyping Assay for Enhanced Surveillance and Pandemic 
Preparedness 
Kathy Rowlen, InDevR, USA 
 
Molecular quality engineering for low cost vaccine production 
Kerry Love, Massachusetts Institute of Technology, USA 
 
High-resolution systems biology modeling of human-virus interactions 
Brandon Xia, McGill University, Canada 
 





Dinner on your own 
Wednesday, June 20, 2018 
 
07:00 – 08:30 Breakfast 
 
08:30 – 10:30 Session 5: Formulation and Delivering Vaccines 
Session Chairs: Nathalie Garcon, Bioaster, France; 
Lakshmi Krishnan, NRC, Canada 
 
08:30 – 09:10 Lead talk: 
Formulation considerations for the development of adjuvanted vaccines 
Dr. Jean Haensler, Director, Antigen & Adjuvant Design, Production and Characterization 
Research Department, Sanofi Pasteur, Lyon, France 
 
09:10 – 09:30 Intradermal administration of synthetic DNA vaccines induce robust cellular and humoral 
immune responses 
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA 
 
09:30 – 09:50 Thermostabilization of adenovirus-vectored vaccines, removing the need for continual 
cold-chain storage 
Alexander Douglas, Jenner Institute, University of Oxford, United Kingdom 
 
09:50 – 10:10 Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine 
adjuvants 
Mike McCluskie, National Research Council, Canada 
 
10:10 – 10:30 Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 
subunit vaccine development 
Suh-Chin Wu, Institute of Biotechnology, National Tsing Hua University, Taiwan 
 
10:30 – 11:00 Coffee break (Sponsored by Intravacc) 
 
11:00 – 13:00 Session 6: Capacity Building and Intervention Plan for Emerging and Re-emerging    
Infectious Diseases (I) 
Session Chairs: Amadou A. Sall, Institute Pasteur Dakar, Senegal; 
Erin Sparrow, WHO, Geneva; 
Simone Blayer, CEPI, UK 
 
11:00 – 11:20 Accelerated process development and stockpile for MERS, LASSA AND NIPAH viral 
vaccine 
Simone Blayer, CEPI, UK 
 
11:20 – 11:40 Rapid response pipeline for stabilized subunit vaccines 
Keith Chappell, University of Queensland, Australia 
 
11:40 – 12:00 Using the AdVac® vaccine manufacturing platform for rapid response to infectious 
disease outbreaks 
Guus Erkens, Janssen Vaccines, Leiden, Netherlands 
 
12:00 – 12:20 Preclinical development of filovirus and flavivirus vaccines based on recombinant insect 
cell expressed subunits 
Axel T. Lehrer, University of Hawaii, USA 
 
12:20 – 12:40 Development of Pan-filovirus vaccine against Ebola and Marburg virus challenges 
Xiangguo Qiu, Public Health Agency of Canada, Canada 
 
12:40 – 13:00 High-titer rapid response platform for epidemic preparedness 
José Castillo, Univercells, Belgium 
 
13:00 – 14:00 Lunch  
Wednesday, June 20, 2018 (continued) 
 
14:00 – 15:30 Workshop 4: Analytical Tools in Vaccine Development 
Moderators: Nathalie Garcon, Bioaster, France; 




Structure-based vaccine design by electron microscopy 
Bridget Carragher, NanoImaging Services Inc., USA 
 
Strategies to overcome the age-old problem of immunosenescence 
Brian Schanen, Sanofi, USA 
 
VaxArray NA reagent kit 
Kathy Rowlen, InDevR, USA 
 
Laser force cytology for rapid quantification of viral infectivity 
Sean J. Hart, LumaCyte, USA 
 
Panel Discussion (all speakers) 
 
15:30 – 16:00 Coffee break (Sponsored by LumaCyte) 
 
16:00 – 18:30 Session 6: Capacity Building and Intervention Plan for Emerging and Re-emerging    
Infectious Diseases (II) 
Session Chairs: Amadou A. Sall, Institute Pasteur Dakar, Senegal; 
Erin Sparrow, WHO, Geneva; 
Simone Blayer, CEPI 
 
16:00 – 16:40 Lead talk: 
Vaccines for poverty. Associated infection diseases: Accessing innovation 
Jerome Kim, Director-General International Vaccine Institute, Seoul, South Korea 
 
16:40 – 17:00 Future prospects and application for the development of adenovirus-based vaccine 
Tao Zhu, Cansino Biologics, China 
 
17:00 – 17:20 Adjuvant manufacturing scale-up and technology transfer 
Christopher Fox, IDRI, USA 
 
17:20 – 17:40 A vaccine for Ebola virus – approaches and results of accelerated process development 
and characterization studies 
Randi Saunders, Merck & Co, USA 
 
17:40 – 18:00 Product development and programmatic implementation of TYPBAR TCV® and 
ROTAVAC® vaccines 
V. K. Srinivas, Bharat Biotech International Limited, India 
 
18:30 – 20:00 Dinner 
 
20:00 – 22:00 Poster session 2 and Social Hour
Thursday, June 21, 2018 
 
07:00 – 08:30 Breakfast 
 
08:30 – 10:30 Session 7: Therapeutic Vaccines 
Session Chairs: Barry Buckland, BioLogicB, USA; 
Paula Alves, IBET, Portugal 
 
08:30 – 09:10 Lead talk: 
A novel vaccinia virus backbone for the delivery of immunotherapeutic genes 
John Bell, Ottawa Hospital Research Institute, Ottawa, Canada 
 
09:10 – 09:30 HER2 cancer vaccine optimization by combining Drosophila S2 insect cell manufacturing 
with a novel VLP-display technology 
Thomas Jørgensen, ExpreS2ion Biotechnologies, Denmark 
 
09:30 – 09:50 Rapid design/development and clinical deployment of synthetic DNA vaccine technology 
for difficult immune targets 
David Weiner, The Wistar Institute, USA 
 
09:50 – 10:10 Development of an analytical platform for delivery of recombinant oncolytic viruses 
Gautam Sanyal, Vaccine Analytics LLC, USA 
 
10:10 – 10:30 Leveraging vectored vaccine candidates manufacturing to GMP compatible bioprocesse 
Cristina Peixoto, iBET, Portugal 
 
10:30 – 11:00 Coffee break (Sponsored by Merck and Co., Inc.) 
 
11:00 – 12:00 Session 8: Short talks selected from poster abstracts    
(Sponsored by Thermo Fisher Scientific) 
 Session Chairs: Yvonne Thomassen, Intravac, Netherlands; 
Ernesto Chico, CIM, Cuba; 
Marc Aucoin, University of Waterloo, Canada; 
Amine Kamen, McGill University, Canada 
 
Purification of flavivirus VLPs by a two-step chromatographic process 
Matheus Souza, Federal University of Rio de Janeiro (UFRJ), Brazil 
 
Flavivirus production in perfusion processes using the EB66® cell line 
Alexander Nikolay, Max Planck Institute for Dynamics of Complex Technical Systems, Germany 
 
Production and characterization of HER2-displaying budded virus-like particles and their 
potential as cancer vaccines 
Lisa Nika, University of Natural Resources and Life Sciences, Vienna, Austria 
 
Virus-like particles: A flexible platform for universal influenza vaccine development 
Sarah Slack, University College London, United Kingdom 
 
Rapid virus titration using flow cytometry 
Steve George, Sanofi Pasteur, Canada 
 
Defining the multiplicity and type of infection for the production of Zaire Ebola virus-like 
particles in the insect cell baculovirus expression system 
Ana Ruth Pastor, Instituto de Biotecnologia-UNAM, Mexico 
 
Combining novel and traditional approaches of vaccine development to overcome the 
challenges of first-in-human trial for Group A Streptococcus 
Elodie Burlet, VaxForm, USA 
 
Development of suspensions adapted Vero cell culture process for production of viruses 
Chun Fang Shen, National Research Council, Canada 
Thursday, June 21, 2018 (continued) 
 
A pre-fusion, trimeric subunit influenza HA-based vaccine elicits cross-protection between 
highly divergent influenza A viruses 
Christopher McMillan, University of Queensland, Australia 
 
HER1 therapeutic cancer vaccine: An active immunotherapy treatment for patients with 
tumors expressing the receptor of epidermal growth factor (EGF-R) 
Eduardo Suarez, CIM, Cuba 
 




14:30 – 15:00 Coffee break (Sponsored by NIIMBL) 
 
15:00 – 16:00 Session 9: Bioprocessing Advances in Vaccine Manufacturing (III) 
Session Chairs: Linda Lua, University of Queensland, Australia; 
Richard Peluso, Merck and Co., USA 
 
15:00 – 15:20 Production of bacterial outer membrane vesicles as vaccine platform 
Matthias Gerritzen, Intravacc, Wageningen University and Research, Netherlands 
 
15:20 – 15:40 Extended gene expression for HIV-1 VLPs scale-up and production enhancement using 
shRNA and chemical additives 
Laura Cervera Gracia, Universitat Autònoma de Barcelona, Spain 
 
15:40 – 16:00 Development of scalable manufacturing process and GMP-compatible formulation for a 
novel recombinant schistosomiasis vaccine 
Damon R. Asher, MilliporeSigma, USA 
 
16:30 – 17:30 Closing Keynote 
Innovations in global health: What has been accomplished, what is on the horizon and 
where are more investments needed 
David Robinson, Deputy Director CMC Vaccines Development and Surveillance at the Bill & 
Melinda Gates Foundation, USA 
 
19:00 – 20:00 Reception 
 
20:00 – 22:00 Banquet 
Friday, June 22, 2018 
 
07:00 – 08:30 Breakfast 
 
08:30 – 10:00 Check out and departures 
Poster Presentations  
 
1.  Stability evaluation of inactivated influenza H7N9 vaccines derived from adhesion and 
suspension MDCK cells 
Alan Yung-Chih Hu, NIIDV/NHRI, Taiwan 
 
2.  Rapid, cost-effective and scalable gmp-compliant simian adenovirus-vectored vaccine 
production for early-phase clinical trials using entirely disposable product-contact 
components 
Alexander Douglas, University of Oxford, United Kingdom 
 
3.  Flavivirus production in perfusion processes using the EB66® cell line 
Alexander Nikolay, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
4.  Latest advancements in process intensification to support global demand for affordable 
vaccines 
Alfred Luitjens, Batavia Biosciences, Netherlands 
 
5.  Proteomic characterization of influenza H1N1 Gag virus-like particles and extracellular 
vesicles produced in HEK-293SF 
Alina Venereo-Sanchez, McGill University, Canada 
 
6.  Implementation of a process-scale adenovirus purification with a single-use platform 
Amélie Boulais, Sartorius Stedim Biotech, France 
 
7.  Membrane chromatography cassettes for bind and elute applications of viruses and 
large proteins 
Stefan Fischer-Frühholz, Sartorius Stedim Biotech, France 
 
8.  Influenza virus capture using membrane chromatography: Improving selectivity by 
matrix design and pseudo-affinity ligand interactions 
Stefan Fischer-Frühholz, Sartorius Stedim Biotech, France 
 
9.  Defining the multiplicity and type of infection for the production of Zaire Ebola Virus-like 
particles in the insect cell baculovirus expression system 
Ana Ruth Pastor, Instituto de Biotecnología, UNAM, Mexico 
 
10.  Structure-based vaccine design by electron microscopy 
Anette Schneemann, NanoImaging Services, USA 
 
11.  Reducing risks with a serum-free medium for MRC-5 based vaccine production 
Anna-Barbara Hachmann, Thermo Fisher Scientific, Inc., USA 
 
12.  Process economical effects of implementation of ready-to-use micro carriers in cell-
based virus vaccine production 
Nicolas Seve, Anne Marie Beauchard, Sanofi Pasteur, France 
 
13.  Bioprocess engineering of insect cells for accelerating vaccines development 
Antonio Roldao, iBET, Portugal 
 
14.  A scalable adenovirus production process, from cell culture to purified bulk 
Åsa Hagner-McWhirter, GE Healthcare, Sweden 
 
 
15.  Vaccine protein stabilization in silica 
Aswin Doekhie, University of Bath, United Kingdom 
 
16.  Experimental and computational fluid dynamics studies of adherent cells on 
microcarriers in an ambr® 250 bioreactor 
Barney Zoro, Sartorius Stedim Biotech, United Kingdom 
 
17.  From bench scale to pilot plant operation: Business models and challenges in the 
biopharmaceutical industry in Brazil 
Beatriz de Castro Fialho, Bio-Manguinhos/FIOCRUZ, Brazil 
 
18.  Immunization with Fc-based recombinant Epstein-Barr virus gp350 elicits potent 
neutralizing humoral immune response in a BALB/c mice model 
Bing-chun Zhao, Sun Yat-sen University Cancer Center, China 
 
19.  Strategies to overcome the age-old problem of immunosenescence 
Brian Schanen, Sanofi Pasteur, USA 
 
20.  Development and validation of a proprietary medium formulation for recombinant 
subunit vaccines by the Baculovirus Expression Vector System (BEVS) 
Catherine Cleuziat, Boehringer-Ingelheim, France 
 
21.  Development of an animal-component free insect medium for the Baculovirus 
Expression Vector System (BEVS) 
Catherine Nguyen, Irvine Scientific, USA 
 
22.  How to limit the use of serum in viral processes: A gibco perspective 
Céline Martin, Thermo Fisher Scientific, Inc., USA 
 
23.  A pre-fusion, trimeric subunit influenza HA-based vaccine elicits cross-protection 
between highly divergent influenza A viruses 
Christopher McMillan, The University of Queensland, Australia 
 
24.  Superinfection arising in stable lentiviral vector producer cell lines bearing Cocal-G 
envelope proteins 
Christopher Perry, University College London, United Kingdom 
 
25.  Development of suspensions adapted Vero cell culture process for production of 
viruses 
Chun Fang Shen, National Research Council of Canada, Canada 
 
26.  Addressing the challenges of influenza virus-like particles purification 
Cristina Peixoto, iBET, Portugal 
 
27.  A genome-wide CRISPR screen to generate high-yield cell lines for pandemic influenza 
vaccine production 
David M. Sharon, McGill University, Canada 
 
28.  Process development for a flexible vaccine vector platform based on recombinant life 
virus 
Dieter Palmberger, ACIB - Austrian Center of Industrial Biotechnology, Austria 
 
29.  HER1 therapeutic cancer vaccine: An active immunotherapy treatment for patients with 
tumors expressing the receptor of epidermal growth factor (EGF-R) 
Eduardo Suarez, CIM, Cuba 
 
30.  Combining novel and traditional approaches of vaccine development to overcome the 
challenges of first-in-human trial for Group A Streptococcus 
Elodie Burlet, VaxForm, USA 
 
31.  Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell 
cultures by reverse genetics 
Ernest Milián, VCN Biosciences, Spain 
 
32.  Implementation of a strategy to produce a broadly neutralizing monoclonal antibody 
against Zika and dengue viruses 
Esmeralda Cuevas-Juárez, Instituto de Biotecnología, UNAM, Mexico 
 
33.  Optimization of a flocculation step using a scale-down model with 3D-printed impellers 
and Focused Beam Reflectance Measurement (FBRM) particle-size monitoring 
Francis DiGennaro, Merck & Co., Inc., USA 
 
34.  Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces 
broad protection against influenza virus challenge in mice 
Guha Asthagiri Arunkumar, Icahn School of Medicine at Mount Sinai, USA 
 
35.  A new porcine suspension cell line (PBG.PK-21) provides efficient production for 
influenza and yellow fever vaccine viruses 
Gwendal Gränicher, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
36.  HILIC-LC/MS method for non-derivatized amino acid analysis in spent media 
Hari Kosanam, Merck, USA 
 
37.  Process development of chromatography-based purification on pandemic influenza 
virus-like particle based vaccines 
Hiachun Lai, NHRI, NTHU, Taiwan 
 
38.  Δπ=0 reverse osmosis enriches a high osmotic pressure solution from a low-titre 
fermentation broth to a saturated solution or salt form using RO and NF membranes 
Ho Nam Chang, Korea Advanced Institute of Science and Technology, South Korea 
 
39.  Upstream process intensification using Viral Sensitizer technology 
Jean-Simon Diallo, Ottawa Hospital Research Institute, Canada 
 
40.  Molecular understanding of the serum antibody repertoires after seasonal influenza 
vaccination among different age cohorts 
Jiwon Jung, The University of Texas at Austin, USA 
 
41.  Formulation development of a recombinant protein based non-replicating rotavirus 
(NRRV) vaccine candidate: Antigen-adjuvant-preservative interactions 
John M. Hickey, University of Kansas, USA 
 
42.  Disruptive micro-facility for affordable vaccine manufacturing 
José Castillo, Univercells, Belgium 
 
43.  Orbital shaken bioreactor for influenza A virus production in high cell density 
cultivations 
Juliana Coronel, Max Planck Institute for Dynamics of Complex Technical Systems, Germany 
 
44.  Vaxarray for hemagglutinin and neuraminidase potency testing of influenza vaccines 
Kathy Rowlen, InDevR, Inc., USA 
45.  Vaxarray potency assay for rapid assessment of “pandemic” flu vaccines 
Kathy Rowlen, InDevR, Inc., USA 
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